Introduction

Hepatitis C virus (HCV) is an enveloped, positivesense, single-stranded RNA virus belonging to the Hepacivirus genus of the Flaviviridae family [1]. HCV infection is one of the major reasons for chronic liver diseases and if not treated on time, often leads to liver cirrhosis and hepatocellular carcinoma. It is estimated that approximately 71 million people are chronically infected with HCV worldwide [2]. HCV is classified into 7 genotypes (GTs), the most common GT globally being GTs 1 and 3 [3]. Furthermore, these GTs are further classified into subtypes such as a, b, c etc representing nuances within specific GTs [3]. In Europe including Sweden, like globally, GTs 1 and 3 are more prevalent compared to other GTs [4,5].

Until 2011, treatment for chronic HCV infections constituted pegylated interferon alpha (pegIFN-α) and ribavirin combination, given for 24 or 48 weeks. The success rates for curing the patients were approximately 80% for GTs 2 and 3, and 40 – 50% for GT 1 [6]. However, after the advent of direct-acting antivirals (DAAs), a successful cure can be accomplished at as high rates as 95 – 99% for some GTs and drug combinations. The DAAs can be classified into NS3/protease inhibitors (PIs), NS5A inhibitors, NS5B nucleoside analog inhibitors (NI) and NS5B non-nucleoside analog inhibitors (NNI) [7]. The NNIs bind to sites outside of the active site and changes the conformation of the NS5B protein by an allosteric mechanism. The structure of HCV NS5B polymerase enables four different binding sites for the NNIs, two of these binding sites are in the thumb region while two other sites are in the palm region [8]. Resistance against NNIs occurs more frequently than NI because of the less conserved regions surrounding the NNI binding sites. Currently, only dasabuvir (i.e. under NS5B NNI class) has been approved and marketed to treat HCV GT 1 infections [9,10]. It binds to one of the two NNI binding sites in the palm region. Dasabuvir, marketed alone as Exviera in Europe, has been used in combination with Viekirax which contains the protease inhibitor paritaprevir and the NS5A inhibitor ombitasvir. In the US, the combination of dasabuvir, paritaprevir and ombitasvir is marketed as Viekira Pak [11–13].

Poor fidelity of the viral RNA dependent RNA polymerase (RdRP) and a high virion production in HCV are...
the main reasons for the development of resistance when using NNIs [14]. Additionally, suboptimal treatment regimens and non-compliance accelerate the mutation rates [15–17]. The emergence of resistance mutations in NS5B can occur in two ways; by a transition or by a transversion substitution. In general, a transition substitution has a lower energy and evolutionary barrier, and therefore occur more frequently than a transversion substitution [18,19]. The resistance-associated substitutions (RAs) against dasabuvir have been extensively characterized in the Kati et al study [20]. This study reported that dasabuvir is primarily active against GTs 1a and 1b. The predominant dasabuvir NS5B RAs in GT 1a viruses are C316Y and S556G. In GT 1b, the predominant RAs are C316Y and M414T. Studies have also reported treatment failure cases associated with the RAs C316N, M414T, A553T, G554S, S556R, G558R, D559G/N and Y561H in GT 1a viruses and C316Y/N, M414I and S556G in GT 1b viruses [11,21–23].

The aim of this present study was to develop and evaluate a semi-pan-genotypic population sequencing method to identify NNI-associated RAs in 54 treatment-naïve patients harboring GT 1a, 1b, 2b and 3a. The predominant dasabuvir NS5B RAs in GT 1a viruses are C316Y and S556G. In GT 1b, the predominant RAs are C316Y and M414T. Studies have also reported treatment failure cases associated with the RAs C316N, M414T, A553T, G554S, S556R, G558R, D559G/N and Y561H in GT 1a viruses and C316Y/N, M414I and S556G in GT 1b viruses [11,21–23].

Material and methods

**Patient samples**

Serum samples collected from 54 patients earlier were retrieved from the biobanks at Clinical Microbiology, Uppsala University hospital (ethical approval Dnr 2009/023). All samples came from patients with a known ongoing HCV infection and had previously been genotyped. The patients were treatment naïve to NS5B inhibitors and also to other DAAs.

**Primer design**

Degenerate primers given in Table 1 were designed using sequence data from the NCBI database. The accession numbers for reference GTs 1a, 1b, 2b, 3a and 4a used were AF011751, FJ390398, AY232749, JN714194 and Y11604, respectively. A total of 47 sequences were aligned and primer sites were picked from the NS5B region. Primer design was performed using OligoAnalyzer version 3.1 (https://eu.idtdna.com/calc/analyzer).

**RNA extraction, cDNA synthesis and nested PCR**

RNA was extracted from the serum samples by using the bioMérieux’s NucliSENS easyMAG system and cDNA from RNA was synthesized by using the Invitrogen™ Superscript III reverse transcriptase. Applied Biosystems’s GeneAmp PCR system 9700 was used for synthesizing cDNA from RNA. The reverse transcription conditions used were as follows: 1 cycle at 25°C for 1 min, 1 cycle at 42°C for 60 min, 1 cycle at 85°C for 5 min and finally hold at 4°C.

Nested PCR was done using the Applied Biosystems’ TaqMan Universal PCR Master Mix. The NS5B primers used for the first round and the second round nested PCRs are given in Table 1. For the first round PCR, the reaction mixture consisted of 12.5 μL of the TaqMan’s Master Mix (2X), 0.4 μL 1st forward and 1st reverse primers each and finally 3 μL of the cDNA with a total volume of 25 μL. The PCR program consisted of 1 cycle at 94°C for 4 min, 35 cycles (94°C for 30 sec, 50°C for 30 sec, and 72°C for 1.5 min), then a final extension at 72°C for 5 min and hold at 4°C. For the second (nested) PCR, 2 μL of the first round PCR product was used. The other components (including the concentrations) were the same as the first round PCR except here we used 2nd forward and 2nd reverse primers. Likewise, the PCR program was also the same except here the annealing was done at 55°C. The amplified products were later verified on 1.5% agarose gel. QiAquick PCR Purification Kit from QiAGEN was used, according to the manufacturer’s guidelines, to clean and purify all the positive samples.

**Population sequencing and mutation analysis**

Sanger sequencing was done using primers 2nd forward and 2nd reverse and Seq forward and Seq reverse as given in Table 1. Sequences were analyzed for the mutation(s) using the SeqScape Software v2.6 from Applied Biosystems with the NS5B of HCV GT 1a strain H77 (accession number: AF011751) as a reference. Clinically relevant variants between the residues 310 and 564 were inspected and compared to known clinically relevant NS5B NNI class RAs put forth by the HCV drug development advisory group [7,24].

**In silico docking of dasabuvir with HCV NS5B polymerase and molecular dynamics (MD) simulations**

The three-dimensional structure of dasabuvir was generated with the compound’s SMILES (PubChem

### Table 1. List of primers used in this study for sequencing of HCV NS5B region by the population sequencing method.

| Primers | Sequence 5’ to 3’ | Position in HCV genome (H77) |
|---------|------------------|-----------------------------|
| 1<sup>st</sup> forward | TAGGAYAACCCTGGTYTTYGA | 8256–8275 |
| 1<sup>st</sup> reverse | GGGCGAYGHGACABGCTGTGA | 9303–9282 |
| 2<sup>nd</sup> forward | ACCCCGTYTGGACTCVAC | 8262–8281 |
| 2<sup>nd</sup> reverse | GACAGCTGGWAGATADATGTC | 9295–9276 |
| Seq forward | ACAGAGGaCTATGACTAGGA | 8519–8638 |
| Seq reverse | CAGGARTRACGGRGATGTG | 8824–8805 |
The HCV NS5B polymerase (GT 1b, isolate BK) crystal structure with PDB ID: 4MKB [25] was retrieved from the protein data bank (https://www.rcsb.org/pdb/home/home.do). It should be noted that the NS5B sequence from the GT 1b isolate BK already possesses C316N substitution.

The NS5B crystal structure was prepared for docking (i.e. removal of solvents and ligands) using AutoDockTools v1.5.6. AutoDock Vina [26] and iGEMDOCK [27] programs were used for the in silico docking studies. While running the AutoDock Vina, the exhaustiveness was set to ‘80’ while the number of output poses was set to ‘20’. The search space for docking was defined by a box of size 30 x 30 x 30 (in Å³) with coordinates X = -9.054, Y = 8.528 and Z = 8.545. For the iGEMDOCK, the population size, the generations and the number of solutions were set to 1000, 150 and 50, respectively. The search space was automatically assigned by iGEMDOCK from the provided NS5B crystal structure bound to the ‘28V’ ligand. From the docking data, a consensus binding pose predicted by both the programs was selected and used for further MD simulations.

MD simulations were performed using GROMACS version 5.1.1 (http://www.gromacs.org/) [28]. The simulations were run on ‘Rackham’ cluster composed of 334 nodes for a total of 6080 CPUs. The Swedish National Infrastructure (SNIC) provided the advanced computational resources required for the MD simulations through the Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX), under the project SNIC 2017/1–213. The HCV NS5B-dasabuvir system was prepared as follows: the AMBER99SB-ILDN force field parameters [29] were assigned to the NS5B RNA-dependent RNA polymerase using GROMACS, while general AMBER force field (GAFF) [30] parameters were assigned to dasabuvir using ANTECHAMBER [31]. Dasabuvir topologies compatible with GROMACS were then generated with ACYPYE [32]. The system was centered in a dodecahedron simulation box filled with TIP3P water while keeping a solute box distance of 1 nm. Sufficient Na⁺ and Cl⁻ ions were also added to neutralize the system and have a final NaCl concentration of 150 mM. Each system was energy minimized and equilibrated first under NVT ensemble for 100 ps to a final temperature of 300 K using the V-rescale thermostat [33], followed by NPT ensemble for 500 ps. Pressure value of 1 bar. MD simulations of 40 ns were performed with an integration time of 2 fs. During the simulations, all bonds were constrained using the LINCS algorithm [35]. The VERLET cut-off scheme [36] was used with a cut-off of 1.0 nm for the calculation of short-range coulomb and van der Waals interactions, while long-range electrostatic interactions were computed with the PME algorithm [37,38]. Four simulation replicates were performed with randomly generated new starting velocities for the systems, according to Maxwell distribution at 300 K. The resulting molecular dynamics simulations trajectories were analyzed using GROMACS built-in tools.

**Results**

**Distribution of GTs, nested PCR and RASs identified by the population sequencing method**

The 54 samples in our study had the following GT distribution: 1a = 21 (38.9%), 1b = 5 (9.3%), 2b = 9 (16.7%) and 3a = 19 (35.1%). Nested PCR was performed on these samples and we found that for GT 1a 20 out of 21 (95%) samples were amplified successfully, for GT 1b 5 out of 5 (100%) samples were amplified successfully, for GT 2b 8 out of 9 (91%) samples were amplified successfully and finally for GT 3a 18 out of 19 (96%) samples were successfully amplified. Thus, in total there were 51 out of 54 samples (94%) sent for the population sequencing. Good sequence quality was defined by SeqScape® software as > 20% tolerance for improper sequencing. As can be seen in Table 2, A553V and C445F were a baseline polymorphism (i.e. found in 100% of samples) in GTs 2b and 3a. Two of the 5 GT 1b samples had C316N RAS, while 8 and 4 of the 8 GT 2b samples had C445F and S556G RASs, respectively. Eighteen out of 18 GT 3a samples had A553V and S556G RASs.

**Modeling of the NS5B-dasabuvir complex**

A model or crystal structure of dasabuvir bound to HCV NS5B polymerase is not yet available. However, the pattern of resistance observed locates the dasabuvir binding site to the palm I of the NS5B polymerase [20,39]. In order to better understand and study dasabuvir RASs, we predicted the dasabuvir’s binding pose in complex with HCV NS5B polymerase using the in silico molecular docking and MD simulations’ methods. The HCV (GT 1b) NS5B polymerase, PDB ID: 4MKB [25], was used as a receptor to predict the dasabuvir’s binding pose. In the aforementioned PDB file, NS5B was co-crystallized with the compound ‘28V’ (PubChem ID 46220530) that is structurally related to dasabuvir (Figure 1(A,B)). Since the two compounds share a similar structure, we speculated that they might also share a similar binding pose and that the favorable conformation of the binding site would allow for a reliable predication of the dasabuvir binding pose.

Two programs namely, AutoDock Vina and iGEMDOCK were used for the molecular docking. The selection of the predicted correct dasabuvir
The binding pose was guided by the knowledge of the compound 28V’s binding pose and the binding pose reliability was further increased by choosing consensus results generated by both the docking programs. Therefore, from the results of each docking programs, consensus binding poses more similar to the compound 28V’s binding pose were considered correctly docked and were selected (Figure 1(A,B)). The agreement between the selected binding poses from both programs was evaluated by calculating the agreement between the selected binding poses from both programs was evaluated by calculating
the relative root-mean-square deviation (RMSD). The selected binding poses had a very low RMSD value of 0.63 Å, demonstrating that a consensus binding pose shared by both programs were successfully identified.

To investigate the NS5B-dasabuvir complex’s stability over time, the dasabuvir binding pose selected from the AutoDock Vina results was used as an input for the MD simulations. A total of 4 simulations of the NS5B-dasabuvir complex and NS5B alone, with each run of 40 ns, was performed using GROMACS. The stability of NS5B and NS5B-dasabuvir complex over time was determined by estimating the RMSD and the radius of gyration (Rg). As it can be seen in Figure 2(A,B), the RMSD of NS5B-dasabuvir complex and NS5B alone was comparable (i.e. lower than 0.2 nm). In particular, the average RMSD of both NS5B-dasabuvir complex and NS5B alone was 0.12 nm with a relative standard deviation of 0.012 nm and 0.011 nm, respectively. The Rg of NS5B-dasabuvir complex oscillated more during the simulations compared to the NS5B alone (Figure 2(C,D)), but the average values 2.43 nm (standard deviation = 0.01) and 2.42 nm (standard deviation = 0.007), respectively were almost identical further proving the high structural stability of NS5B independently from the presence or absence of dasabuvir. The conformational stability of dasabuvir was also assessed by calculating its RMSD during the whole simulation time. As it can be seen in Figure 2(D), dasabuvir had minimal structural variations during all the simulation replicas with values oscillating mainly between 0.05 and 0.1 nm and an average RMSD value of 0.08 nm (standard deviation = 0.02). Overall, these findings suggested that dasabuvir had no effects on NS5B’s structural stability and the binding pose generated by molecular docking was very stable during the entire simulation period. In order to identify the most representative NS5B-dasabuvir complex from the 4 simulation replicas, a cluster analysis of 1000 frames from the last 10 ns of each simulation trajectories were then performed. In each run, we found only one cluster of NS5B-dasabuvir complex conformation. This confirms

![Figure 2](image-url)

**Figure 2.** NS5B backbone root-mean-square deviation (RMSD) and radius of gyration (Rg) plotted with respect to time. The RMSD fluctuation of NS5B in complex with dasabuvir and of the free NS5B are shown in pictures (A,B), respectively. Similarly, the radius of gyration (Rg) of NS5B in complex with dasabuvir and the free NS5B are shown in pictures (C,D), respectively. In picture E, the RMSD fluctuation of dasabuvir over time is shown. The different simulation replicate is color coded as follows: the first simulation is shown in black, second simulation is shown in green, third simulation in red and fourth simulation in blue.
that the NS5B-dasabuvir complex was very stable during the MD simulations as stated above. The most representative NS5B-dasabuvir conformation from each one of the four clusters was then saved and compared to each other by the RMSD calculation. The NS5B-dasabuvir complex structure, representative of the 4th simulation’s cluster, was more similar to all the other analyzed structures from the remaining three clusters and was selected as the NS5B-dasabuvir complex with correct binding pose.

Structure analysis of NS5B-dasabuvir complex and RASs implicated in dasabuvir resistance

Ideal dasabuvir’s binding pose with HCV NS5B polymerase predicted in our study is shown in Figure 3. In this model, dasabuvir extends from the β-hairpin loop, formed by the residues L443 to I454 of the thumb domain, towards the NS5B active site. In particular, dasabuvir formed hydrogen bonds with the side chains of residues 288, 291 and 318 located close to the active site and with the backbone of residues 447 and 448 of the β-hairpin loop. This β-hairpin loop blocks the double stranded primer-template’s exit and it has to undergo an extensive conformational change to allow the elongation process [40]. However, dasabuvir might prevent such conformational change by interacting with residues 447 and 448 and overall stabilizing the β-hairpin loop. This is in accordance with the hypothesized general mode of action for the palm I binding non-nucleoside inhibitors, which are thought to bind and stabilize this β-hairpin loop thereby keeping the viral polymerase in an auto-inhibitory conformation [41]. In Figure 3, it can also be observed that a molecule of water makes a hydrogen bond with dasabuvir and residue 446 possibly further contributing to the stabilization of the β-hairpin loop.

Mutation at residue positions 316, 414, 448 and 556 are associated with resistance to dasabuvir in both GTs 1a and 1b. In our model, these residues were found to be involved in shaping the dasabuvir binding pocket. In particular, the backbone of residue Y448 forms a hydrogen bond with dasabuvir while the other residues have their side chains facing the binding site and might be involved in van der Waals and other types of non-covalent interactions with dasabuvir. Dasabuvir also forms hydrogen bonds with the residues 288, 291 and 318. However, these residues are more conserved as previously shown and D318 is one of the residues constituting the NS5B polymerase’s active site [42]. Moreover, the importance of the residue position 291 was demonstrated by Ishii et al. which found that by introducing the mutations N291A and T287A in recombinant NS5B completely abolished the polymerase activity [43]. In our study, we found a high prevalence of variants C445F, A553V and S556G in both GTs 2b and 3a. The precise locations of C445 in the thumb β-hairpin loop, and A553 and S556 that are found in the NS5B C-terminal tail are shown in Figure 4.

Discussion

It is well-known that the outgrowth of RASs during treatment failure can depend on negative factors such as baseline RASs with high-fold resistance towards DAAs. However, the general consensus is to recommend a cut-off level of 10 – 20%, for detecting RASs within the HCV quasispecies, in
order to be of clinical relevance in predicting the viral failures [7,24]. Thus, the population sequencing method (or the next generation sequencing method set at a cut-off level of 10 – 20%) is thought to be the optimal method. In this study, we investigated the presence of baseline RASs in patient samples against the NNI dasabuvir by the population sequencing method. The population sequencing method was carried out on 54 treatment-naive samples (GTs 1a, 1b, 2b and 3a) adopting the common cut-off level of ~20% for RASs detection.

There are only a handful of studies claiming to have designed HCV pan-genotypic primers covering all the DAA resistance sites in either NS3 protease or NS5A or NS5B regions [44]. As already pointed out in the Bartlett et al. review article [44], we have shown here that our designed primers are semi-pan-genotypic for the most prevalent HCV GTs globally (i.e. 1a, 1b, 2b and 3a), and covers the key NNI-DAA resistance sites in the NS5B region. It should be noted that the second set of primers designed by us (used for the nested PCR in this study) has been earlier reported in the review article [44]. Yet, the complete primers’ list has been unveiled only in this study.

By the population sequencing method, no RAS was found in GT 1a samples while the RAS C316N was found in 40% of GT 1b samples. The RAS C316N represents a baseline polymorphism of GT 1b (10.9 – 35.6%) associated with low level of resistance against dasabuvir (5-fold increase in effective concentration_{50}) [7,20]. High prevalence of variants C445F, A553V and S556G were found in both GTs 2b and 3a. The variants C445F and S556G have also been previously reported as baseline polymorphisms with natural prevalence ranging from 96 to 100% for GT 2 and from 97.1 to 100% for GT 3 [7,42,45,46]. Additionally, the natural prevalence of the variant A553V was reported to be 96% for GT 2 and 97.1% for GT 3 [46]. The variant A553V is associated with a high level (> 100-fold increase in effective concentration_{50}) of resistance against dasabuvir in GT 1b replicon assay [20]. On the other hand, C445F and S556G are associated with low level of resistance (16 and 11-folds increase in effective concentration_{50} for C445F and S556G mutations, respectively) against dasabuvir in GT 1b replicon assay [20]. The mutations C445F, A553V and S556G found as a baseline polymorphism for GTs 2 and 3, they are considered resistance mutations towards dasabuvir for GT 1b [7,20]. All these RASs are located in the dasabuvir binding site in the palm I region of the HCV NS5B polymerase. In particular, the residue 445 is located in the β-loop that extends from the NS5B thumb while the residues 553 and 556 are located in the NS5B C-terminal tail. The possible negative effect of mutations at sites 445 and 556 are more evident than at position 553. In fact, as it can be seen, residue C445 is in close proximity to residues 446 and 448 which directly interact with dasabuvir while the residue S556 side chain is oriented towards dasabuvir and it is involved in shaping the dasabuvir binding site. However, the A553V mutation confers higher level of resistance compared to the mutations at residue positions 445 and 556. The role of NS5B C-terminus tail in conferring NNI resistance has been studied previously [47]. In the study performed by Boyce et al. (2014), the recombinant NS5B constructs namely Δ39 (C-terminus ending at position 552), Δ47 (C-terminus ending at position 544) and Δ55 (C-terminus ending at position 536), had more than 100-fold inhibitory concentration_{50} (IC_{50}) increase against the palm one protease inhibitor A-837093[47]. The RAS A553V could cause structural changes of NS5B C-terminal tail that ultimately could result in the variation of the β-hairpin loop position through the interaction formed between the β-hairpin loop itself and the NS5B C-terminal tail. Such repositioning of key elements of dasabuvir binding site could have important effects on dasabuvir’s binding affinity towards the palm I site of the NS5B.

The presence of the variants C445F, A553V and S556G as a baseline polymorphism in GTs 2 and 3 might explain why dasabuvir, in combination with ombitasvir and paritaprevir, is approved only for the treatment of GT 1 patients [11]. Since dasabuvir is used only to treat GT 1 patients, there is no information on the possible negative impact of these variants on the treatment of other HCV GTs. Nevertheless, it could be expected that the variants A553V and S556G

Figure 4. Location of residues 445, 533 and 556 in the dasabuvir binding site. (a) Front view and (b) Back view. In the picture, the β-hairpin loop is colored in yellow and the C-terminal tail in purple. As it can be seen, both the β-hairpin loop and C-terminal domain form a predominant part of the dasabuvir (colored in orange) binding site.
in GTs 2 and 3 would cause the same negative effect on dasabuvir efficacy reported for GT 1 even if the extent of the impact is not easily predictable.

To conclude, we did not find any potential clinically relevant RAS against dasabuvir in GT 1a and 1b samples by the population sequencing method. It is worth pointing out, that RASs against dasabuvir have very little impact on the treatment of GT 1b patients as reported by clinical trials [9,21–23,48,49] and literature reporting real life treatment data [30]. The known RASs C445F, A553V and S556G were found as baseline polymorphisms in GT 2b and 3a samples. These residues belong to the NSSB’s β-hairpin loop and C-terminal tail which form a predominant part of the dasabuvir binding site and thereby essential for the NNI inhibitory activity. Mutation of these residues could alter the conformation of the β-hairpin loop and in turn the shape of the dasabuvir binding pocket thereby possibly making the drug ineffective against GTs 2b and 3a.

**Acknowledgements**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This study was supported by the Uppsala-Örebro Regional Research Council (RFR-651021 and RFR-744511), the Erik, Karin and Gösta Selander Foundation and the Scandinavian Society for Antimicrobial Chemotherapy (SLS-692951).

**Notes on contributors**

Dario Akaberi performed his BSc studies at Ferrara University, Italy and his Master studies at Uppsala University. Dario currently works in Johan Lennerstrand’s research group at Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Assar Bergfors did his MEng at Uppsala University, and has contributed with expertise in bioinformatics in the project when working in Johan Lennerstrand’s research group at Clinical Microbiology, Uppsala University. Assar currently works at Agilent Technologies, Stockholm.

Midori Kjellin graduated in 2000 from Uppsala University with a Master of Science in molecular biology. She is currently doing her PhD studies in Johan Lennerstrand’s group in the field of HCV DAA resistance, in parallel with work as a microbiologist at the Molecular Virology department, Clinical Microbiology, Akademiska Hospital, Uppsala University, Uppsala, Sweden.

Nader Kameli did his Master studies at Uppsala University and he conducted his master project with Johan Lennerstrand’s research group. He started this study by retrieving samples, extracting RNA, performing nested PCR (including primers designing) and analyzing the mutations. He is a faculty member in College of Applied Medical sciences at Jazan University, Saudi Arabia. He is currently doing his PhD studies at Maastricht University.

Louise Lidemalm did her BSc at Swedish university of agricultural sciences and her Master studies at Uppsala University and she conducted her master project 2015 in Johan Lennerstrand’s research group. She is currently working in Öscar Fernández-Capetillo research group at Karolinska Institutet, Stockholm.

Bhavya Kolli did her Master studies at Uppsala University 2013–2015 and she conducted her master project in Johan Lennerstrand research group.

Robert W. Shafer is a Professor of Medicine and Pathology in the Division of Infectious Diseases at Stanford University. He is an authority on the mechanisms and consequences of HIV evolution. Dr. Shafer created an online database (http://hivdb.stanford.edu) that assists epidemiologists in performing HIV drug surveillance, physicians in interpreting HIV drug resistance tests, and basic scientists in developing new antiretroviral drugs.

Navaneethan Palanisamy is currently a PhD student at the Heidelberg University, Heidelberg, Germany. His research interests include HCV and zoonotic pathogens: epidemiology, evolution, drug discovery, development and resistance, computational biology, immunology, chemical biology and cell biology.

Johan Lennerstrand received his PhD in Medical Virology in 1996 at Uppsala University, Sweden. In 2005, he became an Associate Professor in Experimental Virology at Karolinska Institutet, Stockholm. He is currently at Section of Clinical Microbiology, Department of Medical Sciences, Uppsala University, and his research involves antiviral drug resistance and drug discovery.

**ORCID**

Navaneethan Palanisamy [http://orcid.org/0000-0003-0369-2316](http://orcid.org/0000-0003-0369-2316)

**References**

[1] Miller RH, Purcell RH. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus superfamilies. Proc Natl Acad Sci U S A. 1990;87:2057–2061.

[2] Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:845–857.

[3] Nakano T, Lau GMY, Lau GML, et al. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 2012;32:339–345.

[4] Alberti A, Laco In L, Morais E, et al. Literature review of the distribution of hepatitis C virus genotypes across Europe. J Med Virol. 2016;88:2157–2169.
[5] Palanisamy N, Danielsson A, Kokkula C, et al. Implications of baseline polymorphisms for potential resistance to NS5 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013;99:12–17.

[6] Hoffmann-La Roch. Antiviral drugs advisory committee. Briefing document for Pegasys® in combination with ColegusTM. 2002 Nov 14 [cited 2018 Apr 18]. Available from: https://www.fda.gov/ohrms/dockets/ac/02/briefing/3909B1_01_Hoffman-LaRoche.pdf

[7] Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.

[8] Sofia MJ, Chang W, Furman PA, et al. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem. 2012;55:2481–2531.

[9] Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV. New England J Med. 2014;370:1983–1992.

[10] Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. New England J Med. 2013;368:34–44.

[11] European medicines agency. European public assessment report. Exvierra: ANNEX I, SUMMARY OF PRODUCT CHARACTERISTICS [Internet]. 2018 May [cited 2018 Aug 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182333.pdf.

[12] European medicines agency. European public assessment report. Viekirax: ANNEX I, SUMMARY OF PRODUCT CHARACTERISTICS [Internet]. 2018 Jul [cited 2018 Aug 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf.

[13] Mantry PS, Dasabuvir PL. (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review. Expert Rev Anti Infect Ther. 2016;14:157–165.

[14] Ogata N, Alter HJ, Miller RH, et al. Characterization of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A. 1991;88:3392–3396.

[15] Friddell RA, Wang C, Sun J-H, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54:1924–1935.

[16] McCown MF, Rajayaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother. 2008;52:1604–1612.

[17] Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013;207:S33–S39.

[18] Götte M. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. Curr Opin Virol. 2012;2:644–650.

[19] Powdrill MH, Tchesnokov EP, Kozak RA, et al. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A. 2011;108:20509–20513.

[20] Kati W, Koev G, Irvin M, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015;59:1505–1511.

[21] Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. New England J Med. 2014;370:1594–1603.

[22] Poordad F, Hezode C, Trinh R, et al. ABT-450/r–ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New England J Med. 2014;370:1973–1982.

[23] Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. New England J Med. 2014;370:1604–1614.

[24] Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–1632.

[25] Schoenfeld RC, Bourdet DL, Brameld KA, et al. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. J Med Chem. 2013;56:8163–8182.

[26] Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010;31:455–461.

[27] Yang J-M, Chen –C-C. GEMDOCK: a generic evolutionary method for molecular docking. Proteins. 2004;55:288–304.

[28] Hess B, Kutzner C, van der Spoel D, et al. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2004;4:833–842.

[29] Lindorff-Larsen K, Piana S, Palmo K, et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins. 2010;78:1950–1958.

[30] Wang J, Wolf RM, Caldwell JW, et al. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157–1174.

[31] Wang J, Wang W, Kollman PA, et al. Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model. 2006;25:247–260.

[32] Sousa da Silva AW, Vranken WF. ACYPPE - AnteChamber PYthon parser interface. BMC Res Notes. 2012;5:367.

[33] Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. J Chem Phys. 2007;126:014101.

[34] Parrinello M, Rahman A. Polymorphic transitions in single crystals: a new molecular dynamics method. J Appl Phys. 1981;52:7182–7190.

[35] Hess B. P-LINCS: a parallel linear constraint solver for molecular simulation. J Chem Theory Comput. 2008;4:116–122.

[36] Verlet L. Computer “Experiments” on classical fluids. I. Thermodynamical properties of lennard-jones molecules. Phys Rev. 1967;159:98–103.

[37] Darden T, York D, Pedersen L. Particle mesh Ewald method. J Chem Phys. 1993–94:10089–10092.

[38] Essmann U, Perera L, Berkowitz ML, et al. A smooth particle mesh Ewald method. J Chem Phys. 1995;103:8577–8593.

[39] Liu Y, Lim BH, Jiang WW, et al. Identification of aryl dihydroxycaril derivatives as palm initiation site inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett. 2012;22:3747–3750.

[40] Deyl J, D’Abramo CM, Zhao Z, et al. High resolution footprinting of the hepatitis C virus polymerase NS5B in complex with RNA. J Biol Chem. 2007;282:16907–16916.
[41] Powers JP, Piper DE, Li Y, et al. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J Med Chem. 2006;49:1034–1046.

[42] Di Maio VC, Cento V, Mirabelli C, et al. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother. 2014;58:2781–2797.

[43] Ishii K, Tanaka Y, Yap CC, et al. Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding. Hepatology. 1999;29:1227–1235.

[44] Bartlett SR, Grebely J, Eltahla AA, et al. Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: a systematic review. Hepatol Commun. 2017;1:379–390.

[45] Patiño-Galindo JA, Salvatierra K, González-Candelas F, et al. Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother. 2016;60:2402–2416.

[46] Palanisamy N, Kalaghatgi P, Akaberi D, et al. (2018) Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals. Antivir Ther. Advance online publication. Doi:10.3851/IMP3237.

[47] Boyce SE, Tirunagari N, Niedziela-Majka A, et al. Structural and regulatory elements of HCV NS5B polymerase–β-loop and C-terminal tail–are required for activity of allosteric thumb site II inhibitors. PLoS ONE. 2014;9:e84808.

[48] Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64:301–307.

[49] Welzel TM, Asselah T, Dumas EO, et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. Lancet Gastroenterol Hepatol. 2017;2:494–500.

[50] Wedemeyer H, Craxi A, Zuckerman E, et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis. J Viral Hepat. 2017;24:936–943.